NCT03838926 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
| NCT ID | NCT03838926 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Vanda Pharmaceuticals |
| Condition | Relapsed or Refractory Hematologic Malignancies |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2018-09-27 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 42 participants in total. It began in 2018-09-27 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.
Eligibility Criteria
Inclusion Criteria: * Subject is ≥ 18 years at the time of signing informed consent; * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies; * Presence of measurable or evaluable disease; * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2; * Contraceptives or other approved avoidance of pregnancy measures Exclusion Criteria: * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression; * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted); * Undergone major surgery ≤ 2 weeks prior to starting study drug; * Evidence of mucosal or internal bleeding; * Impaired cardiac function or conduction defect; * Concurrent severe and/or uncontrolled medical conditions
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03838926 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Relapsed or Refractory Hematologic Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03838926 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03838926 currently recruiting?
Yes, NCT03838926 is actively recruiting participants. Contact the research team at clinicaltrials@vandapharma.com for enrollment information.
Where is the NCT03838926 trial being conducted?
This trial is being conducted at Washington D.C., United States, Lafayette, United States, Hackensack, United States, Seattle, United States and 7 additional locations.
Who is sponsoring the NCT03838926 clinical trial?
NCT03838926 is sponsored by Vanda Pharmaceuticals. The trial plans to enroll 42 participants.